Cited by 901Cardiac Ischemia and ReperfusionDiabetes Treatment and ManagementAcute Myocardial Infarction Research

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, Lazaros A., Mankad, Sunil, Sokos, George G., Miske, Glen, Shah, Ankur, Elahi, Dariush, Shannon, Richard P.·2004·Circulation

DOI 10.1161/01.cir.0000120505.91348.58

Open this paper in CoChat — free account

Abstract

Background— Glucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion. Methods and Results— We investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients. Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion. Baseline demographics and background therapy were similar, and both groups had severe LV dysfunction at baseline (LVEF=29±2%). GLP-1 significantly improved LVEF (from 29±2% to 39±2%, P <0.01), global wall motion score indexes (1.94±0.11→1.63±0.09, P <0.01), and regional wall motion score indexes (2.53±0.08→2.02±0.11, P <0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects. Conclusions— When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000120505.91348.58

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year
Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils
Leaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605
Glucagon-Like Peptides
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598
Metabolic Modulation of Acute Myocardial Infarction
Díaz, R., Paolasso, E., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J., Romero, G., & Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction
van der Horst, I. C. C., Zijlstra, F., Hof, A. W. J. V. ’., Doggen, C. J. M., de Boer, M., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 259
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships
Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207
Insulin therapy as an adjunct toreperfusion after acute coronary ischemia
Sack, M. N., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00164-5 · Cited by 105
Glucose-Insulin-Potassium for Acute Myocardial Infarction
Apstein, C. S. (1998) · Circulation · doi:10.1161/01.cir.98.21.2223 · Cited by 95

Show all 15 references

Research works printed but not linked: 4

10.1161/circ.96.4.1074 · DOI
10.1161/circ.98.21.2227 · DOI
10.1161/circ.98.21.2223 · DOI
1987, Am Heart J, 102, 1038

Sorted by citations

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Myocardial Reperfusion Injury
Yellon, D. M., & Hausenloy, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071667 · Cited by 3,797
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes
Kolwicz, S. C., Purohit, S., & Tian, R. (2013) · Circulation Research · doi:10.1161/circresaha.113.302095 · Cited by 838
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Self-citation
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 644
Pathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for Therapy
Turer, A. T., & Hill, J. A. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.032 · Cited by 635
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Cardiovascular consequences of metabolic syndrome
Tune, J. D., Goodwill, A. G., Sassoon, D., & Mather, K. J. (2017) · Translational research · doi:10.1016/j.trsl.2017.01.001 · Cited by 645
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 556
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E. O., Helqvist, S., Saunamäki, K. I., Clemmensen, P. M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 534
Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
Bozkurt, B., Aguilar, D. A., Deswal, A. M., Dunbar, S. B., Francis, G. S., Horwich, T. B., Jessup, M. L., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 556
The incretin system and its role in type 2 diabetes mellitus
Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection
Hausenloy, D. J., & Yellon, D. M. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9026-1 · Cited by 516
Postconditioning and protection from reperfusion injury: where do we stand?Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology
Ovize, M., Baxter, G. F., Lisa, F. D., Ferdinandy, P., David Garcia-dorado, A., Hausenloy, D. J., Heusch, G., Vinten-Johansen, J., Yellon, D. M., & Schulz, R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq129 · Cited by 502
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Paul Steendijk, A., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 471
The Reperfusion Injury Salvage Kinase Pathway: A Common Target for Both Ischemic Preconditioning and Postconditioning
Hausenloy, D. J., Tsang, A., & Yellon, D. M. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.03.001 · Cited by 449
DPP4 in diabetes
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 458
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Diabetic cardiomyopathy - A comprehensive updated review
Murtaza, G., Virk, H. U. H., Khalid, M. F., Lavie, C. J., Ventura, H. O., Mukherjee, D., Ramu, V. K., Bhogal, S. S., Kumar, G., Shanmugasundaram, M., et al. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.03.003 · Cited by 364
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Gastrointestinal hormones regulating appetite
Chaudhri, O. B., Small, C. J., & Bloom, S. R. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 362
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Glucose metabolism and cardiac hypertrophy
Kolwicz, S. C., & Tian, R. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr071 · Cited by 302
Preconditioning and postconditioning: Underlying mechanisms and clinical application
Hausenloy, D. J., & Yellon, D. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.029 · Cited by 304
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Initial human trials mimicked cellular and animal model studies, with GLP-1 therapies improving left ventricular (LV) function in patients with acute myocardial infraction (AMI) and serve systolic dysfunction (206).”
Result
Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts
Zhao, T., Parikh, P., Bhashyam, S., Bölükoglu, H., Poornima, I. G., Shen, Y., & Shannon, R. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.100982 · Cited by 298
Self-citation
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 298
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart
Sonne, D. P., Engstrøm, T., & Treiman, M. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 291
Preconditioning and postconditioning: United at reperfusion
Hausenloy, D. J., & Yellon, D. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.005 · Cited by 285
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274
Self-citation
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells
Shiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 265
Effect of Glucagon-Like Peptide-1 (GLP-1) on Glycemic Control and Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Grafting
Sokos, G. G., Bölükoglu, H., German, J., Hentosz, T. M., Magovern, G. J., Maher, T. D., Dean, D. A., Bailey, S. H., MARRONE, G. C., Benckart, D. H., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.022 · Cited by 253
Self-citation
Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 255
The therapeutic potential of ischemic conditioning: an update
Hausenloy, D. J., & Yellon, D. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.85 · Cited by 242
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations
Hausenloy, D. J., Baxter, G. F., Bell, R., Bøtker, H. E., Davidson, S. M., Downey, J. M., Heusch, G., Kitakaze, M., Lecour, S., Mentzer, R. M., et al. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0121-4 · Cited by 244
Self-citation
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Borghetti, G., von Lewinski, D., Eaton, D., Sourij, H., Houser, S. R., & Wallner, M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01514 · Cited by 253
Hyperglycemia in Acute Ischemic Stroke: A Vascular Perspective
Martini, S. R., & Kent, T. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600355 · Cited by 242
Effects of Bariatric Surgery on Cardiovascular Function
Ashrafian, H., le Roux, C. W., Darzi, A. W., & Athanasiou, T. (2008) · Circulation · doi:10.1161/circulationaha.107.721027 · Cited by 228
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 237
Protective Factors and the Pathogenesis of Complications in Diabetes
Yu, M. G., Gordin, D., Fu, J., Park, K., Li, Q., & King, G. L. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad030 · Cited by 252
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
Read, P. A., Khan, F. Z., Heck, P. M., Hoole, S. P., & Dutka, D. P. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.899377 · Cited by 226
Optimized Treatment of ST-Elevation Myocardial Infarction
Niccoli, G., Montone, R. A., Ibáñez, B., Thiele, H., Crea, F., Heusch, G., Bulluck, H., Hausenloy, D. J., Berry, C., Stiermaier, T., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315344 · Cited by 227
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.001 · Cited by 222
Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Woo, J. S., Kim, W., Ha, S. J., Kim, J., Kim, S., Kim, W.-S., Seon, H. J., & Kim, K. S. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301586 · Cited by 223
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Frederich, R. C., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R. K., Wolf, R., & Mahaffey, K. W. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2138 · Cited by 216
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Fadini, G. P., & Avogaro, A. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.05.001 · Cited by 213
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Sarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 216
DPP-4 inhibitors
Åhrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 210
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Abu‐Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1296 · Cited by 203
Self-citation
Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Nuche‐Berenguer, B., Moreno, P., Esbrit, P., Dapía, S., Caeiro, J. R., Cancelas, J., Haro‐Mora, J. J., & Villanueva‐Peñacarrillo, M. L. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9220-3 · Cited by 192
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
DPP4 in Cardiometabolic Disease
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 190
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186
New Drugs for the Treatment of Diabetes
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 188
Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
Poornima, I. G., Brown, S. B., Bhashyam, S., Parikh, P., Bölükoglu, H., & Shannon, R. P. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 183
Self-citation
Mitochondrial Pathways, Permeability Transition Pore, and Redox Signaling in Cardioprotection: Therapeutic Implications
Penna, C. R. R., Perrelli, M.-G., & Pagliaro, P. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4459 · Cited by 182
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 179
Cardiac Metabolism as a Target for the Treatment of Heart Failure
Taegtmeyer, H. (2004) · Circulation · doi:10.1161/01.cir.0000139340.88769.d5 · Cited by 178
Molecular Mechanisms of Right Ventricular Failure
Reddy, S., & Bernstein, D. (2015) · Circulation · doi:10.1161/circulationaha.114.012975 · Cited by 174
Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction
Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2016.01.008 · Cited by 165
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Halbirk, M., Nørrelund, H., Møller, N., Holst, J. J., Schmitz, O., Nielsen, R. R., Nielsen‐Kudsk, J. E., Nielsen, S. S., Nielsen, T. T., Eiskjær, H., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00930.2009 · Cited by 165
Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population
Schweizer, A., Dejager, S., Foley, J. E., Couturier, A., Ligueros‐Saylan, M., & Kothny, W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01215.x · Cited by 162
Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
Patil, H., Badarin, F. J. A., Shami, H. A. A., Bhatti, S. K., Lavie, C. J., Bell, D. S. H., & O’Keefe, J. H. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.061 · Cited by 161
The Effects of Bariatric Surgery on Cardiac Structure and Function: a Systematic Review of Cardiac Imaging Outcomes
Aggarwal, R., Harling, L., Efthimiou, E., Darzi, A. W., Athanasiou, T., & Ashrafian, H. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1866-5 · Cited by 159
Diabetic cardiomyopathy
Asghar, O., Alsunni, A. A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A. S., Heagerty, A. M., & Malik, R. A. (2009) · Clinical Science · doi:10.1042/cs20080500 · Cited by 162
The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
The diabetic cardiomyopathy
Tarquini, R., Lazzeri, C., Pala, L., Rotella, C. M., & Gensini, G. F. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0180-x · Cited by 155
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 154
Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes
Teodoro, J. S., Nunes, S., Rolo, A. P., Reis, F., & Palmeira, C. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01857 · Cited by 150
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 173
Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145

Authors: Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P.
Affiliations: Allegheny General Hospital (US)
ORCID: Nikolaidis, Lazaros A.
Mankad, Sunil
Sokos, George G.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-03-02
Volume: 109
Issue: 8
Pages: 962-965
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000120505.91348.58
OpenAlex: W1968315455
Cited by: 901
References: 15
Citations by year: 2026: 9 · 2025: 16 · 2024: 25 · 2023: 18 · 2022: 17 · 2021: 25 · 2020: 27 · 2019: 38 · 2018: 37 · 2017: 46 · 2016: 48 · 2015: 63 · 2014: 71 · 2013: 80 · 2012: 92
FWCI: 16.30
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Pittsburgh Foundation
National Institutes of Health (5r01ag023125-05)
National Institute on Aging (1 R01 AG023125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: glucagon-like peptide-1, acute myocardial infarction, left ventricular dysfunction, primary percutaneous coronary intervention, reperfusion, left ventricular ejection fraction, regional wall motion, incretin-based therapy, glucose-insulin-potassium infusion, systolic dysfunction
MeSH terms: Adult, Aged, Aged, 80 and over, Blood Glucose, Combined Modality Therapy, Glucagon-Like Peptides, Female, Glucagon, Humans, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Pilot Projects, Safety, Stroke Volume, Angioplasty, Balloon, Coronary, Ventricular Function, Left, Treatment Outcome, Diabetes Complications, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks